Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 4, 2010, Pages 456-463

  Gatell, Jose M ^a   Katlama, Christine ^b   Grinsztejn, Beatriz ^c   Eron, Joseph J ^d   Lazzarin, Adriano ^e   Vittecoq, Daniel ^f   Gonzalez, Charles J ^g   Danovich, Robert M ^h   Wan, Hong ⁱ   Zhao, Jing ⁱ   Meibohm, Anne R ⁱ   Strohmaier, Kim M ⁱ   Harvey, Charlotte M ⁱ   Isaacs, Robin D ⁱ   Nguyen, Bach Yen T ⁱ  

^a UNIVERSITY OF BARCELONA   (Spain)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Funda??o Oswaldo Cruz   (Brazil)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f HÔPITAL PAUL BROUSSE   (France)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ Percepticore LLC   (United States)

Author keywords

AIDS; Antiretroviral therapy; HIV; Integrase inhibitor; Raltegravir; Resistance

Indexed keywords

ENFUVIRTIDE; PLACEBO; RALTEGRAVIR;

ACUTE HEART INFARCTION; ACUTE PANCREATITIS; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEART ARREST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; KIDNEY FAILURE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPLEEN ABSCESS; SUICIDE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRROLIDINONES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77949381837     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181c9c967     Document Type: Article

References (16)

1. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000; 287:646-650.
2. Miller M, Witmer M, Stillmock K, et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor. Presented at: 16th International AIDS Conference; Toronto, Canada; August 2006 [Abstract THAA0302].
3. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-näive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009; 52:350-356.
4. Grinsztejn B, Nguyen B-Y, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007;369:1261-1269.
5. Steigbigel RT, Cooper DA, Eron JE, et al. 96-Week results from BENCHMRK 1 &2, phase III studies of raltegravir (RAL) in patients (pts) failing antiretroviral therapy (ART) with triple-class resistant HIV. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; February 2009 [Abstract K-103].
6. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-681.
7. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008; 359:355-365.
8. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
9. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
10. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466-475.
11. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178.
12. Fätkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008; 359:1442-1455.
13. Miller MD, Danovich RM, Ke Y, et al.Longitudinal analysis of resistance to the HIV-1 integrase inhibitor raltegravir: results from P005, a phase 2 study in treatment experienced patients [abstract #6]. Presented at: XVII International HIV Drug Resistance Workshop; Sitges, Spain; 10-14 June 2008.
14. Havlir DV, O'Marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004;38:1599-1604.
15. Dicenzo R, Luque A, Larppanichpoonphol P, et al. Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens. J Antimicrob Chemother. 2006;58:393-400.
16. Grinsztejn B, Nguyen B-Y, Katlama C, et al. 48 week efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; September 2007 [abstract #H-713].